BriaCell Therapeutics Corp.
BCT.TO
TSX
| 01/31/2026 | 10/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -8.83% | 13.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.51% | -2.71% | |||
| Operating Income | 9.51% | 2.71% | |||
| Income Before Tax | 11.86% | -1.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.86% | -1.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -7.05% | 11.14% | |||
| Net Income | 11.90% | -1.31% | |||
| EBIT | 9.51% | 2.71% | |||
| EBITDA | 9.54% | 2.71% | |||
| EPS Basic | 40.78% | 52.83% | |||
| Normalized Basic EPS | 41.44% | 52.67% | |||
| EPS Diluted | 40.71% | 52.89% | |||
| Normalized Diluted EPS | 41.44% | 52.67% | |||
| Average Basic Shares Outstanding | 48.75% | 114.79% | |||
| Average Diluted Shares Outstanding | 48.75% | 114.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||